P/E ratio for Aurinia Pharmaceuticals (AUPH)
P/E ratio as of May 2024 (TTM): -9.75
According to Aurinia Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -9.75472. At the end of 2022 the company had a P/E ratio of -5.68.
P/E ratio history for Aurinia Pharmaceuticals from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -5.68 | -64.96% |
| 2021 | -16.2 | 0.86% |
| 2020 | -16.1 | 3.19% |
| 2019 | -15.6 | 71.39% |
| 2018 | -9.09 | 130.85% |
| 2017 | -3.94 | 23.8% |
| 2016 | -3.18 | -25.29% |
| 2015 | -4.26 | -19.27% |
| 2014 | -5.28 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Regeneron Pharmaceuticals REGN | 25.1 | -357.28% | 🇺🇸 USA |
 Pieris Pharmaceuticals PIRS | -30.4 | 211.42% | 🇺🇸 USA |
 Aeterna Zentaris AEZS | -0.4313 | -95.58% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.